Novartis deal on the rocks, page-137

That is useful. But I think that backs up my previous position in the context of the massive outperformance endpoint criteria for study success.

It means that the study would have been knocked out at the 45% mark if it was not showing some kind of superiority and a reasonable one at that). I would bet that less 1% probability of the study catching up to finish 43% ahead on superiority at the trial end even if both arms were equal at the 45% futility analysis.

I asked kervio to give us some bounds of the two arm performance at those futility analysis points now that we know the target outcome for the study.